


Comparative effect of metformin versus sulfonylureas with dementia and Parkinson's disease risk in US patients over 50 with type 2 diabetes mellitus

Danielle Newby ^{1,2} Andrew Brent Linden,³ Marco Fernandes,¹ Yasmina Molero,^{4,5} Laura Winchester,¹ William Sproviero,¹ Upamanyu Ghose,¹ Qingqin S Li,⁶ Lenore J Launer,⁷ Cornelia M van Duijn,^{3,8} Alejo J Nevado-Holgado¹

To cite: Newby D, Linden AB, Fernandes M, *et al*. Comparative effect of metformin versus sulfonylureas with dementia and Parkinson's disease risk in US patients over 50 with type 2 diabetes mellitus. *BMJ Open Diab Res Care* 2022;**10**:e003036. doi:10.1136/bmjdr-2022-003036

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bmjdr-2022-003036>).

Received 12 July 2022
Accepted 28 August 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to
Dr Danielle Newby;
danielle.newby@ndorms.ox.ac.uk

ABSTRACT

Introduction Type 2 diabetes is a risk factor for dementia and Parkinson's disease (PD). Drug treatments for diabetes, such as metformin, could be used as novel treatments for these neurological conditions. Using electronic health records from the USA (OPTUM EHR) we aimed to assess the association of metformin with all-cause dementia, dementia subtypes and PD compared with sulfonylureas.

Research design and methods A new user comparator study design was conducted in patients ≥ 50 years old with diabetes who were new users of metformin or sulfonylureas between 2006 and 2018. Primary outcomes were all-cause dementia and PD. Secondary outcomes were Alzheimer's disease (AD), vascular dementia (VD) and mild cognitive impairment (MCI). Cox proportional hazards models with inverse probability of treatment weighting (IPTW) were used to estimate the HRs. Subanalyses included stratification by age, race, renal function, and glycaemic control.

Results We identified 96 140 and 16 451 new users of metformin and sulfonylureas, respectively. Mean age was 66.4 ± 8.2 years (48% male, 83% Caucasian). Over the 5-year follow-up, 3207 patients developed all-cause dementia (2256 (2.3%) metformin, 951 (5.8%) sulfonylurea users) and 760 patients developed PD (625 (0.7%) metformin, 135 (0.8%) sulfonylurea users). After IPTW, HRs for all-cause dementia and PD were 0.80 (95% CI 0.73 to 0.88) and 1.00 (95% CI 0.79 to 1.28). HRs for AD, VD and MCI were 0.81 (0.70–0.94), 0.79 (0.63–1.00) and 0.91 (0.79–1.04). Stronger associations were observed in patients who were younger (< 75 years old), Caucasian, and with moderate renal function.

Conclusions Metformin users compared with sulfonylurea users were associated with a lower risk of all-cause dementia, AD and VD but not with PD or MCI. Age and renal function modified risk reduction. Our findings support the hypothesis that metformin provides more neuroprotection for dementia than sulfonylureas but not for PD, but further work is required to assess causality.

INTRODUCTION

Neurodegenerative diseases, such as dementia and Parkinson's disease (PD), are progressive degenerative diseases affecting neurons, which

WHAT IS ALREADY KNOWN ON THIS TOPIC

- ⇒ People with type 2 diabetes have increased risk of dementia and Parkinson's disease (PD) and antidiabetic drugs such as metformin have been proposed as potential novel treatments for these neurological conditions.
- ⇒ Observational studies have shown inconsistent results regarding the effect of metformin on the risk of dementia and PD.

WHAT THIS STUDY ADDS

- ⇒ To our knowledge, this study is the largest of its kind and uses a variety of statistical methods to reduce bias and validate the robustness of the results to examine the association of metformin versus sulfonylureas for multiple neurodegenerative outcomes.
- ⇒ This study supports and extends the current literature regarding the potential neuroprotective benefits of metformin.
- ⇒ Further research is required to understand the underlying neuroprotective mechanisms of metformin which may lead to novel drug development opportunities.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

- ⇒ This study highlights the need for randomized clinical trials and genetic studies to confirm our findings to assess causality and understand mechanistic insights which could lead to novel disease-modifying treatments for dementia.
- ⇒ This study highlights the need for careful consideration of age, race, and renal function in selection of participants for clinical trials to address benefits and safety concerns for the repurposing of metformin.

result in irreversible decline in brain functioning. It is estimated there are 50 million people living with dementia worldwide and over 6 million people living with PD, with these numbers predicted to increase substantially over the next decades due to ageing populations.^{1–3}

Type 2 diabetes (diabetes from now on) is a well-established risk factor for dementia⁴ and PD⁵ indicating a potential shared pathophysiology involving insulin resistance and impaired glucose metabolism.^{6–8} Given the potential shared pathophysiology it is not surprising that drugs used to treat diabetes such as metformin are of increased interest for repurposing as possible novel treatments to treat and slow the progression of PD,^{9–10} cognitive decline and dementia.¹¹ Metformin is a first-line antidiabetic medication that decreases insulin resistance and increases insulin sensitivity.¹² Other antidiabetic drugs such as sulfonylureas, which are second-line antidiabetic drugs, stimulate the release of insulin from pancreatic beta cells.¹³ Despite approvals of newer drugs, sulfonylureas remain commonly prescribed after metformin.¹⁴ Previous studies and reviews on the potential neuroprotective properties of metformin have inconsistently reported that metformin is associated with reduced risk of dementia or PD,^{15–17} increased risk,^{18–19} and no association.^{20–22} Differences in study design, data quality, gender, race representation, and confounding may explain some of these inconsistencies.

Given these inconsistencies, the aim of the present study is to examine the associations of the first-line antidiabetic drug metformin compared with the second-line drug class sulfonylureas with: (1) incident all-cause dementia and PD, and (2) with secondary outcomes of Alzheimer's disease (AD), vascular dementia (VD) and mild cognitive impairment (MCI). In this study, we use a large cohort of patient records from individual-level electronic health records from a large healthcare provider in the USA (OPTUM deidentified Electronic Health Records; OPTUM EHR) together with robust methods that address bias and confounding. We carried out subanalysis stratifying our population by age, race, renal function, and glycemic control to understand the impact on these populations. Our approach focusing on both dementia and PD and an analysis approach to reduce bias offer a novel aspect and substantial contribution to existing evidence on the impact of metformin and risk of neurodegenerative diseases.

RESEARCH DESIGN AND METHODS

Study design and setting

A new user active comparator study was carried out to determine the comparative effect of metformin versus sulfonylurea users on dementia risk over a 5-year follow-up based on an intention-to-treat approach. A new user study design includes new users of treatments or diagnosis and excludes prevalent users which can bias results due to baseline covariates being influenced by treatment or disease. The active comparator design refers to a study that compares the effect of the drug of interest with another active drug used in clinical practice. We used OPTUM EHR data set containing data from primary care and secondary care facilities from over 100 million patients across the US general population.²³

We had access to patient data from 1 January 2006 to 1 December 2018 for patients aged 40 years or older. Patient data were mapped to the Observational Medical Outcomes Partnership Common Data Model v5.3.1.²⁴

Participants

We included patients who were 50 years or older with a diagnosis of diabetes and at least 1 year of observational data between 2006 and 2018. Included patients were required to have at least 1 year of observation in the database prior to first prescription of metformin or sulfonylureas (baseline) and be free of any diagnosis of dementia, MCI, or PD prior to their first prescription. Patients with polycystic ovary syndrome were excluded due to off-label use of metformin. Since renal function can drive choice of antidiabetic prescription, included patients were required to have an estimated glomerular filtration rate (eGFR) measure (or related clinical diagnosis) and a hemoglobin A1c (HbA1c) measurement 1 year before metformin or sulfonylurea initiation. Those with chronic kidney disease (CKD) levels 4 and 5 as well as HbA1c level >9% were excluded as this is not indicative of metformin new users. Only patients who remained on monotherapy of either metformin or sulfonylureas for 2 years following first prescription were included in this study. Follow-up began after this 2-year period and lasted until the end of the 5 years, death, or dementia/PD diagnosis, whichever occurred first. During follow-up, participants could take additional diabetes medications, but those who switched between metformin and sulfonylureas were excluded.

Variables and data sources

Comorbidities were defined by standard concept codes based on SNOMED nomenclature using ATHENA (<https://athena.ohdsi.org/search-terms/terms>) and PHOEBE (<https://data.ohdsi.org/PHOEBE/>) tools. Clinical codes used define outcome, exposure and all other variables can be found in the online supplemental tables S1, S2 and S3.

Primary outcomes were all-cause dementia or PD defined using a combination of diagnosis and prescription records. Secondary outcomes included diagnosis of AD, VD and MCI. Metformin or sulfonylurea use was extracted from patient prescriptions defined by standard concept codes based on RxNorm nomenclatures. Sulfonylureas consisted of acetohexamide, carbutamide, chlorpropamide, tolazamide, tolbutamide, glibenclamide (glyburide), glibornuride, gliclazide, glipizide, gliquidone, glisoxepide, glycopyramide or glimepiride. At least two prescriptions per year between baseline and the beginning of follow-up were required.

The 33 covariates used in this study were age (dichotomized at 75 years), gender, body mass index (BMI), race (Caucasian, African American, Asian, other/unknown), smoking status (current, previous, never, missing), US state region, comorbidities (angina, arthritis, atrial fibrillation, cancer, chronic obstructive pulmonary disease,

CKD diagnosis and stages, coronary heart disease, eye disease, hypertension, heart attack, heart failure, high cholesterol, head injury, psychiatric disorders, peripheral arterial disease, substance abuse, stroke), healthcare utilization (number of outpatient visits), year of first prescription, lab measurements (HbA1c, eGFR) and medications (ACE inhibitors, glucocorticoids, non-steroidal anti-inflammatory drugs (NSAIDs), beta-2 agonists, diuretics and angiotensin receptor blockers). For measurement variables (ie, HbA1c, eGFR, BMI, etc), the value closest to baseline date within 1 year before metformin or sulfonylurea prescription was taken unless otherwise stated. BMI was calculated from height and weight when not reported directly. Height measurements within 5 years before baseline were allowed. BMI measurements lower than 15 kg/m² and greater than 60 kg/m² were removed, which is consistent with previous studies.²⁵ For smoking, unknown or contradictory measurements on the same day were removed. HbA1c values ≤2% were removed. CKD stage was extracted from diagnostic codes or from eGFR values. Other medications (ACE inhibitors, NSAIDs, etc) were defined as at least two prescriptions 1 year prior to drug initiation.

Statistical methods

Baseline demographics were assessed using standardized mean differences (SMD). We carried out a new user comparator study²⁶ to estimate the effect of metformin versus sulfonylureas. A new user design excludes prevalent cases to reduce immortal time and survivor biases. To account for confounding by indication, we used propensity scores (PS) and implemented inverse probability of treatment weighting (IPTW)²⁷ to balance the baseline characteristics. To create the PS model, we included 33 variables specified previously. For BMI, smoking status, race and location, the missing indicator method was used to account for missingness.²⁸ This method uses a dummy variable (which can have either a value of 0 or 1) in the statistical model for the PS to indicate whether the value for each variable is missing, with all missing values set to the same value. IPTW was created and trimmed at 20. We assessed balance between our groups using SMD with a difference of less than 0.1 (ie, 10%) indicating an acceptable balance between covariates, with metformin and sulfonylurea users after IPTW.²⁹ Cox proportional hazards models were used with IPTW to estimate the risk of subsequent primary (all-cause dementia, PD) and secondary outcomes (AD, VD, MCI). Cox proportional hazards models are regression models that investigate the effect of several risk factors on survival, or the time it takes for a specific event to happen. The Cox model is expressed by the hazard function denoted by $h(t)$. Briefly, the hazard function can be interpreted as the risk of an event at time t and is determined by a set of covariates (x_1, x_2 , etc) and the baseline hazard ($h_0[t]$) by the following equation: $h(t)=h_0(t)\exp(b_1x_1+b_2x_2+\dots+b_nx_n)$. The proportional hazards assumption was evaluated using Kaplan-Meier (KM) survival curves and a

violation was considered if the survival curves for the different treatment groups crossed over at any point in follow-up. Where proportional hazards assumption was violated, analyses were repeated using piecewise Cox regression. Piecewise Cox regression can be used to estimate HRs at different time periods across follow-up when the HR changes over time. In the present study, where there was a violation of the proportional hazards assumption (based on KM survival curves), periods of follow-up were split where the survival curves crossed. Five negative control outcomes (impacted cerumen, tinnitus, cramp of limb, snoring and impingement syndrome of shoulder region)³⁰ were used to identify residual confounding unaccounted for by IPTW.

We first carried out the analysis using the whole cohort and, secondly, split by age (cut-off 75 years) for primary outcomes (all-cause dementia, PD) and secondary outcomes (AD, VD, MCI) with and without adjustment for IPTW. In subanalyses, we compared the risk of outcome in patients with differing renal function, HbA1c levels and race. We dichotomized eGFR based on CKD staging into three groups (normal (eGFR>90 mL/min), moderate (eGFR=60–89 mL/min) and poor renal function (eGFR≤60 mL/min)), and HbA1c at baseline was dichotomized at 7%, reflecting diabetes treatment guidelines. We additionally carried out a variety of sensitivity analyses to test the robustness of our results. Since diagnosis codes for MCI might capture impairment but this impairment may not be severe enough to qualify as dementia, we carried out a sensitivity analysis by combining diagnostic codes from MCI and dementia. Although patients had been on monotherapy use for 2 years before follow-up there remained the potential for the impact of dementia or PD to influence medication use. Further sensitivity analysis involved excluding those with a dementia or PD diagnosis less than 1 year after follow-up to account for potential protopathic bias (ie, reverse causation). Finally, for the main analysis, we followed an intent-to-treat framework; therefore, we carried out an on-treatment analysis in which discontinued metformin or sulfonylurea use was censored.

RESULTS

Participants

Between 2006 and 2018, we identified 96 140 new users of metformin and 16 451 new users of sulfonylureas (n=112 591). A flow diagram showing how these numbers were obtained after inclusion and exclusion criteria is shown in [figure 1](#).

Characteristics of baseline population

From the study population, the mean age (±SD) was 66.4±8.2 years (metformin users mean age 65.7±7.83 and sulfonylureas mean age 71.0±8.71), 48% male, 83% Caucasian with a mean HbA1c of 6.79%±0.76%. In the sample population, 3207 patients developed any dementia (2256 among metformin and 951 sulfonylurea users) and




Figure 1 Flow diagram sample population for this study after inclusion and exclusion criteria. eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; PCOS, polycystic ovary syndrome; PD, Parkinson's disease.

760 patients developed PD (625 among metformin and 135 sulphonylurea users). All-cause dementia rates were 7.77 and 17.73 per 1000 person-years in metformin and sulphonylurea users, respectively. PD rates were 2.13 and 2.45 per 1000 person-years in metformin and sulphonylurea users, respectively. Metformin users were younger, have better renal function, fewer comorbidities, and take different associated medications (NSAIDs, diuretics and glucocorticoids) compared with sulphonylurea users (table 1). For BMI, 26% of observations were missing (24% for metformin users and 33% for sulphonylurea users) and for eGFR 0.1% of observations were missing (0.08% for metformin users and 0.38% for sulphonylurea users).

After IPTW, all variables were balanced between the two groups for the main analysis (SMD<0.1) (figure 2). For subanalyses (age, race, renal function, and HbA1c), all variables were balanced apart from the race subanalysis where the variable 'HbA1c<7%' was unbalanced for the race group 'unknown/other' (online supplemental figures S1–S11).

Association of new users of metformin versus sulphonylureas with all-cause dementia and PD risk

For primary outcomes, using Cox regression with IPTW, there was a lower risk of all-cause dementia (HR 0.80; 95% CI 0.73 to 0.88) when comparing metformin users with sulphonylurea users, but no difference when comparing risk of PD (HR 1.00; 95% CI 0.79 to 1.27) (figure 3). For secondary outcomes, there was a lower risk of AD (HR 0.81; 95% CI 0.70 to 0.94) but not for VD or MCI. However, for the direction of the effects on VD and MCI, the effects were consistent with lower risk for metformin users.

We found that the associations were stronger in the younger ages (aged <75) for all-cause dementia and secondary outcomes and attenuated in older ages (≥ 75 years) (figure 3). There were fewer patients who started antidiabetic treatment after age 75 compared with before 75 (19% vs 81%, respectively) although average follow-up length was similar (3.04 vs 3.06 years). For PD, the older stratum showed an increased risk of PD for metformin users versus sulphonylurea users. All unadjusted HRs for all models can be found in the online supplemental table S4–S6.

Using KM survival curves, the proportional hazards assumption held for all-cause dementia, AD, MCI, and PD in figure 3 apart from VD where there was deviation of proportional hazards at around 2.5 years (online supplemental figure S12). Therefore, we repeated the analysis for the whole population using a piecewise Cox regression split at 2.5 years. The results showed only a lower HR for metformin users after 2.5 years (HR 0.64; 95% CI 0.45 to 0.89) (online supplemental table S7). For sensitivity analyses, changing to an on-treatment analysis further decreased HRs in favor of metformin for all-cause dementia (HR 0.76; 95% CI 0.68 to 0.84) (online supplemental table S8). Removal of patients who were diagnosed within 1 year of follow-up attenuated results for AD but did not change the results for other outcomes (online supplemental table S9). Combining the earliest dates from MCI and all-cause dementia diagnosis had little impact on results (HR 0.82; 95% CI 0.75 to 0.89). Adjusted HRs for the negative control outcomes were 1.04 (0.96–1.13) for impacted cerumen, 1.10 (0.95–1.30) for tinnitus, 1.01 (0.87–1.18) for cramp in limb,

Table 1 Baseline characteristics of 112 591 patients over 50 years old with type 2 diabetes who were new users of either metformin or sulfonylureas between 2006 and 2018 before balancing of characteristics using inverse probability of treatment weighting (IPTW)

| Description | Metformin | Sulfonylureas | SMD (%) |
|--|---------------|---------------|---------|
| n | 96 140 | 16 451 | |
| Gender (% male) | 46 107 (48.0) | 8439 (51.3) | 6.7 |
| Race (%) | | | 4.3 |
| African American | 9659 (10.0) | 1535 (9.3) | |
| Asian | 2394 (2.5) | 328 (2.0) | |
| Caucasian | 79 693 (82.9) | 13 853 (84.2) | |
| Other/unknown | 4394 (4.6) | 735 (4.5) | |
| Age at baseline (mean (SD)) | 65.65 (7.83) | 70.98 (8.71) | 64.4 |
| Age category: <75 years | 81 258 (84.5) | 9690 (58.9) | 59.3 |
| US region | | | 10.5 |
| Midwest (%) | 51 871 (54.0) | 9232 (56.1) | |
| Northeast (%) | 11 430 (11.9) | 2294 (13.9) | |
| South (%) | 24 678 (25.7) | 3706 (22.5) | |
| West (%) | 6153 (6.4) | 850 (5.2) | |
| Unknown (%) | 2008 (2.1) | 369 (2.2) | |
| eGFR (mean (SD)) | 88.47 (16.43) | 75.48 (21.73) | 67.4 |
| CKD group (%) | | | 67.2 |
| Stage 1 | 46 980 (48.9) | 4464 (27.1) | |
| Stage 2 | 44 276 (46.1) | 7708 (46.9) | |
| Stage 3 | 4884 (5.1) | 4279 (26.0) | |
| Smoking status (%) | | | 18.1 |
| Missing | 39 916 (41.5) | 8078 (49.1) | |
| Current | 7992 (8.3) | 1083 (6.6) | |
| Never | 24 377 (25.4) | 3197 (19.4) | |
| Previous | 23 855 (24.8) | 4093 (24.9) | |
| HbA1c (mean (SD)) | 6.76 (0.75) | 6.95 (0.83) | 24.3 |
| BMI (mean (SD)) | 33.46 (6.63) | 32.24 (6.60) | 18.6 |
| BMI group | | | 25.8 |
| Missing | 23 243 (24.2) | 5481 (33.3) | |
| Underweight (<20 kg/mg ²) | 276 (0.3) | 86 (0.5) | |
| Normal (20–25 kg/mg ²) | 4701 (4.9) | 1084 (6.6) | |
| Overweight (25–30 kg/mg ²) | 18 766 (19.5) | 3302 (20.1) | |
| Obese (>30 kg/mg ²) | 49 154 (51.1) | 6498 (39.5) | |
| HbA1c group | | | 27.3 |
| HbA1c: <7% (<53 mmol/mol) | 62 460 (65.0) | 8583 (52.2) | |
| HbA1c: 7%–8% (53–64 mmol/mol) | 26 245 (27.3) | 5721 (34.8) | |
| HbA1c: >8 (>64 mmol/mol) | 7435 (7.7) | 2147 (13.1) | |
| Length of follow-up in years (mean (SD)) | 3.02 (1.59) | 3.26 (1.60) | 15 |

Continued

Table 1 Continued

| Description | Metformin | Sulfonylureas | SMD (%) |
|---|---------------|---------------|---------|
| Year at first prescription (%) | | | 34.7 |
| 2007–2008 | 9016 (9.4) | 3190 (19.4) | |
| 2009–2010 | 13 001 (13.5) | 2696 (16.4) | |
| 2011–2012 | 21 752 (22.6) | 3748 (22.8) | |
| 2013–2014 | 30 202 (31.4) | 4325 (26.3) | |
| 2015–2016 | 22 169 (23.1) | 2492 (15.1) | |
| Number of outpatient visits prior to baseline (mean (SD)) | 24.36 (30.39) | 25.74 (34.85) | 4.2 |
| All-cause dementia (%) | 2256 (2.3) | 951 (5.8) | 17.5 |
| AD (%) | 754 (0.8) | 337 (2.1) | 11.1 |
| VD (%) | 349 (0.4) | 154 (1.0) | 7.5 |
| MCI (%) | 1414 (1.5) | 401 (2.6) | 7.5 |
| PD (%) | 625 (0.7) | 135 (0.8) | 2 |
| Hypertension (%) | 68 050 (70.8) | 11 601 (70.5) | 0.6 |
| COPD (%) | 5483 (5.7) | 1194 (7.3) | 6.3 |
| Chronic kidney disease (%) | 4655 (4.8) | 2740 (16.7) | 38.9 |
| Stroke/TIA (%) | 2147 (2.2) | 562 (3.4) | 7.1 |
| Heart attack (%) | 954 (1.0) | 224 (1.4) | 3.4 |
| Angina (%) | 11 081 (11.5) | 1898 (11.5) | 0 |
| Heart failure (%) | 2494 (2.6) | 1126 (6.8) | 20.1 |
| Atrial fibrillation (%) | 9636 (10.0) | 2256 (13.7) | 11.4 |
| Coronary artery disease (%) | 1844 (1.9) | 535 (3.3) | 8.4 |
| Substance abuse (%) | 1131 (1.2) | 176 (1.1) | 1 |
| Hyperlipidemia (%) | 69 957 (72.8) | 11 026 (67.0) | 12.5 |
| Head injury (%) | 537 (0.6) | 114 (0.7) | 1.7 |
| Arthritis (%) | 18 726 (19.5) | 3057 (18.6) | 2.3 |
| Major psychiatric disorders (%) | 11 372 (11.8) | 1423 (8.6) | 10.5 |
| Peripheral arterial disease (%) | 3287 (3.4) | 998 (6.1) | 12.5 |
| Eye disease (%) | 3598 (3.7) | 711 (4.3) | 2.9 |
| Cancer (%) | 4275 (4.4) | 981 (6.0) | 6.8 |
| Ace inhibitors (%) | 38 748 (40.3) | 7426 (45.1) | 9.8 |
| Diuretics (%) | 25 846 (26.9) | 3930 (23.9) | 6.9 |
| Beta-2 agonists (%) | 35 593 (37.0) | 5530 (33.6) | 7.1 |
| Angiotensin II receptor blockers (%) | 21 623 (22.5) | 3482 (21.2) | 3.2 |
| Glucocorticoids (%) | 49 438 (51.4) | 8533 (51.9) | 0.9 |
| NSAIDs (%) | 32 424 (33.7) | 4332 (26.3) | 16.2 |

CKD group defined using eGFR and/or diagnosis code. AD, Alzheimer's disease; BMI, body mass index; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate by measured laboratory value using Mayo Clinic Quadratic; HbA1c, hemoglobin A1c; MCI, mild cognitive impairment; NSAID, non-steroidal anti-inflammatory drug; PD, Parkinson's disease; SMD (%), standardized mean difference (values >10% indicate significant imbalance between groups); TIA, transient ischemic attack; VD, vascular dementia.

Covariate Balance




Figure 2 Covariate balance between new users of metformin and sulfonylureas using absolute standardized mean differences (SMD) before (unweighted) and after inverse probability of treatment weighting (weighted) for whole cohort (n=112 591). Dotted line indicates SMD cut-off at 0.1 where >0.1 indicates difference in covariates between the metformin and sulfonylurea users. BMI, body mass index; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; HbA1c, hemoglobin A1c.

1.06 (0.91–1.24) for snoring, and 1.16 (0.96–1.41) for shoulder impingement (online supplemental figure S13 and Table S10).

The influence of race, renal function, and glycemic control between new users of metformin versus sulfonylureas with dementia and PD risk

In subgroup analyses, we explored if our outcomes were influenced by renal function, glycemic control, or race (figure 4).

In the race subgroup analysis, after IPTW adjustment, metformin users who were Caucasian (n=94 395) had a lower risk of all-cause dementia (HR 0.79; 95% CI 0.71 to 0.87), AD (HR 0.77; 95% CI 0.65 to 0.90) or in sensitivity analysis >2.5 years for VD (HR 0.64; 95% CI 0.44

to 0.94, online supplemental table S7). There were no differences for other outcomes compared with sulfonylurea users (figure 4). There were no differences in risk for other races; however, sample numbers were lower (African American 11 224, Asian 2735, and other/unknown 5156). In the renal function subgroup analysis, metformin users with moderate renal function were associated with lower all-cause dementia and AD but no differences in risk for PD for any renal function group (figure 4). For VD, metformin users had a lower HR after 2.5 years (HR 0.59; 95% CI 0.35 to 0.99) (online supplemental table S7). In the glycemic control subgroup analysis, stratifying on baseline HbA1c, metformin users with either low or high HbA1c levels were associated




Figure 3 Forest plot showing IPTW-weighted associations of primary and secondary outcomes with new users of metformin versus sulfonylureas in whole population (over 50) and stratified for patients above and below 75 years of age. IPTW, inverse probability of treatment weighting; MCI, mild cognitive impairment; PD, Parkinson's disease.

with a lower risk of all-cause dementia or AD but only HbA1c \geq 7% levels for VD (HR 0.67; 95% CI 0.48 to 0.94) which in sensitivity analysis showed risk was lower after 2.5 years (HR 0.57; 95% CI 0.35 to 0.93). Unadjusted HRs for all subgroup analyses in figure 4 can be found in the online supplemental table S6.

DISCUSSION

In this new user active comparator study of 112 591 patients with diabetes, we found new metformin users were associated with ~20% lower risk of all dementia, AD and VD compared with sulfonylurea users but there was no difference in PD risk or MCI. A lower risk of dementia in metformin users was also seen in subsets of patients who were younger (<75 years), Caucasian, and those with moderate renal function, but there were no differences in risk in subsets with different glycaemic control. Our findings support the hypothesis that metformin may provide more neuroprotection for dementia than sulfonylureas but not for PD or MCI.

Our results agree with similar active comparator studies, which show a reduction in risk for all-cause dementia in new users of metformin, despite these studies using either smaller, older, or mainly male populations.^{15 16 31} A study using patients older than 65 years from the US Veterans Affairs (VA) database¹⁵ showed a lower risk of all-cause dementia in those younger than 75 years old for metformin users (HR 0.89; 95% CI 0.79 to 0.99; n=28 640) but not for AD or VD. However, a lack of precision in recording specific diagnosis of dementia, with difficulties in discriminating between AD and other causes, is leading to under-reporting of specific dementia diagnosis.³² This could explain why previous studies and

our present study have not shown reduction of risk in dementia disease subtypes when stratifying on age.³³ Our results and three other studies^{15 31 34} differ from other studies^{19 35 36} which report no association or increased risk of dementia in metformin users because these studies did not consider confounding by indication. Therefore, results obtained from these studies may reflect the differences between the characteristics of the antidiabetic drug users rather than true treatment effects. Despite these inconsistencies, a Mendelian randomization study has shown metformin reduces AD risk with the *NDUFA2* gene and mitochondrial function proposed as potential mechanisms in dementia protection.³⁷ For patients with VD, our results showed there was only a lower risk after 2.5 years of metformin treatment concurrent with a previous study²¹ which showed lower risk of dementia and AD after longer term use greater than 2 years in patients from the VA database (n=5528).

We did not find any association between metformin and MCI compared with sulfonylureas. MCI populations could contain a mixture of patients who do or do not convert to dementia. This heterogeneity may have reduced our power to detect any differences. However, a randomized controlled trial in patients with amnesic MCI indicated metformin users had better total recall after 12 months but not for other cognitive tests (Minimal state examination (MMSE), Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog)).³⁸ Interestingly, this trial showed that those who were younger, on the highest dose, without APOE- ϵ 4 and with lower HbA1c had the most benefit.

For PD, there are no active comparator studies which compare new users of metformin versus sulfonylureas-only




Figure 4 Forest plot showing IPTW-weighted associations of primary and secondary outcomes with new users of metformin versus sulfonylureas stratified by race, baseline renal function and baseline HbA1c. Renal function levels were defined as normal (eGFR>90 mL/min), moderate (eGFR=60–89 mL/min) and poor (eGFR≤60 mL/min). HbA1c levels were defined as low <7% and high ≥7%. eGFR, estimated glomerular filtration rate; IPTW, inverse probability of treatment weighting.

direct comparator studies which compare drug use versus no drug use. One study using US veteran data showed those who took metformin >2 years had lower risk of PD (HR 0.30; 95% CI 0.18 to 0.85)²¹ compared with non-users. However, nearly 30% of non-metformin users were taking other antidiabetic medications. These results contradict a study using data from Taiwan which showed metformin users are at increased risk of PD (HR 2.27; 95% CI 1.68 to 3.07).¹⁹ Direct effect studies comparing drug use versus no drug use are prone to confounding by indication and immortal time bias making observational studies difficult to interpret and generalize. Despite inconsistent results of observational studies there is evidence from in vitro, non-clinical and genetic studies which highlight the potential neuroprotective benefits of metformin.^{10 39 40} In a Mendelian randomization study, greater genetically predicted expression level of *NDUFAF2* in brain, the putative target of metformin, was shown to decrease the risk of PD.¹¹ This means that although there was no difference

in risk between metformin users and sulfonylurea users observed in our study, it remains possible that metformin could reduce the risk of PD compared with those not taking metformin or other antidiabetics.

Our age-specific findings are consistent with previous studies which indicate metformin may have more benefits for reducing dementia risk for those who initiate the treatment at a younger age.^{15 31} We also showed that there were, although smaller, benefits in those who were older than 75 years. Differences in study inclusion criteria, demographics and size of patient populations could explain this difference. Moreover, older patients have more comorbidities which contribute to dementia risk and hence attenuate any positive drug effects of metformin. We additionally showed that PD risk was higher in metformin users in those older than 75 years old which is consistent with a recent meta-analysis and systematic review (OR 1.66, 95% CI 1.14 to 2.42)¹⁸; however, our CIs were large and close to the null (HR

1.40; 95% CI 1.01 to 1.95) so caution must be taken with this result. In this study, we found baseline HbA1c levels did not modify the effect of metformin on dementia or PD risk which is also consistent with previous studies.^{15 34} This could indicate that metformin's neuroprotective effect is unlikely to be due to better diabetic control but via other mechanisms.^{34 41}

We did not see protective effects of metformin in different race groups apart from Caucasian patients which were the most represented group in our study (83%). These results are consistent with other studies,^{15 31} but are contradicted by one¹⁶ who showed that African American patients taking metformin were associated with a reduction in dementia risk and no reduction in risk in Caucasian patients. Differences in these results and ours might be explained by our eligibility criteria, which included 2 years of continuous metformin or sulfonylurea use. Our exclusion criteria may have removed patients from under-represented populations who may have a higher burden of diabetes-related complications and may escalate quicker from monotherapy metformin or sulfonylurea use limiting the generalizability of our results.⁴²

For renal function, contradictory to a previous study,¹⁵ we found that metformin users with normal renal function did not have any difference in dementia or PD risk compared with sulfonylurea users. However, this study¹⁵ only categorized renal function into two categories (split by eGFR 60 mL/min) whereas we split renal function into three groups (normal eGFR>90 mL/min, moderate eGFR=60–89 mL/min and poor eGFR≤60 mL/min). Our results indicated that metformin users with poor renal function (eGFR≤60 mL/min) may have reduced dementia and AD risk. However, this group was much smaller potentially due to the contradictions of metformin in those with renal disease.

There are many strengths of this study. First, the large sample size allowed us to investigate the impact of all-cause dementia and specific causes of dementia, such as AD and VD. We used data from both genders unlike other studies which had >90% male populations.^{15 21} We carried out a new user active comparative cohort study design, with IPTW, nested within a population of patients with diabetes to reduce confounding by indication and other biases. We additionally tested five negative control outcomes which provided reassurance that no significant residual confounding remained after adjusting the mentioned covariates using IPTW methods.

Limitations of our study are as follows. First, although we addressed many sources of confounding, it is possible that some sources of confounding were unavailable or inadequately measured such as physical activity, education, and diet.^{4 43} Furthermore, we used data from OPTUM EHR from USA which could reduce the generalizability of our results due to potential differences in prescription patterns, comorbidities, incidence of diabetes and dementia in other countries.

Second, dementia and PD tend to be underdiagnosed and under-recorded,^{32 44} which may lead to measurement errors in our outcomes and would tend to lead associations towards the null. We used both diagnosis and prescription records to define our outcomes which could lead to misclassification due to the off-label use of certain medications.^{45 46} Third, we carried out an intention-to-treat analysis and did not include potential add-on drug treatments that occurred later or consider antidiabetic treatment switches. This may be a possible source of confounding and could result in a lack of generalizability. Fourth, for dementia and PD, there is a long prodromal and/or preclinical periods^{47 48} which may impact treatment choice and, although in our sensitivity analysis we removed those with a diagnosis less than 1 year from the start of follow-up, this might not be long enough to completely remove reverse causation biases. Finally, it has been shown that metformin reduces mortality in patients with diabetes,⁴⁹ therefore the competing risk of death could affect our results and interpretation. A recent study³⁴ jointly modeled the risk of dementia and death with metformin versus sulfonylureas and showed that the competing risk of death is highly dependent on the baseline mortality rate of the population.

CONCLUSIONS

To our knowledge, this study is the largest of its kind and uses a variety of statistical methods to reduce bias and validate the robustness of the results. This study supports and extends the current literature regarding the potential neuroprotective benefits of metformin. The clinical applicability of this study showing potential neuroprotection of metformin is highlighted by recent clinical trials underway investigating metformin for the prevention of cognitive impairment and dementia.^{11 50} Furthermore, a recent genetic study also highlights causal effects between metformin and dementia.³⁷ This work highlights the need for careful consideration of age, race, and renal function in selection of participants for clinical trials to address benefits and safety concerns for the repurposing of metformin. Further research is required to understand the underlying neuroprotective mechanisms of metformin which may lead to novel drug development opportunities.

Author affiliations

¹Psychiatry, University of Oxford, Oxford, UK

²Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK

³Nuffield Department of Population Health, University of Oxford, Oxford, UK

⁴Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institute, Stockholm, Sweden

⁵Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden

⁶Neuroscience, Janssen Research and Development, Titusville, New Jersey, USA

⁷Laboratory of Epidemiology and Population Science, National Institute on Aging, Bethesda, Maryland, USA

⁸Department of Epidemiology, Erasmus MC, Rotterdam, Netherlands

Acknowledgements We thank John Isaac (Janssen Pharmaceuticals) for initial discussions.

Contributors DN designed the study with input from LJJ, QSL and YM. MF carried out the data curation and DN carried out all the analyses. DN wrote the manuscript with input from all authors. All authors reviewed the final manuscript and gave consent for publication. DN (the guarantor) accepts full responsibility for the finished work and/or the conduct of the study, had access to the data, and controlled the decision to publish.

Funding This work was supported by Janssen Pharmaceuticals. LJJ is supported by the National Institute on Aging Intramural Research Program, USA. Additional funds were provided by Rosetrees Trust (M937) and John Black Charitable Fund (ID A2926).

Disclaimer The funding sources have no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Competing interests AJN-H has received funding from Janssen Pharmaceuticals, GlaxoSmithKline and Ono Pharma. QSL is an employee of Janssen Research & Development, Johnson & Johnson, and may hold equity in Johnson & Johnson.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants but OPTUM EHR databases were reviewed by the New England Institutional Review Board (IRB) and were determined to be exempt from IRB approval. Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data may be obtained from a third party and are not publicly available. Data may be obtained from a third party (OPTUM EHR) and are not publicly available.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Danielle Newby <http://orcid.org/0000-0002-3001-1478>

REFERENCES

- Martin Prince A, Wimo A, Guerchet M. *World Alzheimer report 2015 the global impact of dementia an analysis of prevalence, incidence, cost and trends*. Alzheimer's disease international, 2015.
- Ou Z, Pan J, Tang S, et al. Global Trends in the Incidence, Prevalence, and Years Lived With Disability of Parkinson's Disease in 204 Countries/Territories From 1990 to 2019. *Front Public Health* 2021;9.
- RayDorseyE, ElbazA, NicholsE, et al. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the global burden of disease study 2016. *Lancet Neurol* 2018;17:939-53.
- Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet* 2020;396:413-46.
- Hassan A, Sharma Kandel R, Mishra R, et al. Diabetes mellitus and Parkinson's disease: shared pathophysiological links and possible therapeutic implications. *Cureus* 2020;12:e9853.
- Karki R, Kodamullil AT, Hofmann-Apitius M. Comorbidity analysis between Alzheimer's disease and type 2 diabetes mellitus (T2DM) based on shared pathways and the role of T2DM drugs. *J Alzheimers Dis* 2017;60:721-31.
- Athauda D, Foltynie T. Insulin resistance and Parkinson's disease: A new target for disease modification? *Prog Neurobiol* 2016;146:145-146-98.
- Firbank MJ, Yarnall AJ, Lawson RA, et al. Cerebral glucose metabolism and cognition in newly diagnosed Parkinson's disease: ICICLE-PD study. *J Neurol Neurosurg Psychiatry* 2017;88:310-6.
- Agostini F, Masato A, Bubacco L, et al. Metformin repurposing for Parkinson disease therapy: opportunities and challenges. *Int J Mol Sci* 2022;23:398.
- Storm CS, Kia DA, Almramhi MM. Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome. *Nat Commun* 20212021;12:1-14.
- METformin and FINGER Intervention to Prevent Cognitive Impairment and Disability in Older Adults at Risk for Dementia - Full Text View - ClinicalTrials.gov. Available: <https://clinicaltrials.gov/ct2/show/NCT05109169> [Accessed 23 Mar 2022].
- Rojas LBA, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. *Diabetol Metab Syndr* 2013;5:6.
- Sola D, Rossi L, Schianca GPC, et al. Sulfonylureas and their use in clinical practice. *Arch Med Sci* 2015;11:840.
- Roglic G, Norris SL. Medicines for treatment intensification in type 2 diabetes and type of insulin in type 1 and type 2 diabetes in low-resource settings: synopsis of the world Health organization guidelines on second- and third-line medicines and type of insulin for the control of blood glucose levels in nonpregnant adults with diabetes mellitus. *Ann Intern Med* 2018;169:394-7.
- Orkaby AR, Cho K, Cormack J, et al. Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes. *Neurology* 2017;89:1877-85.
- Scherrer JF, Morley JE, Salas J, et al. Association between metformin initiation and incident dementia among African American and white Veterans health administration patients. *Ann Fam Med* 2019;17:352-62.
- Campbell JM, Stephenson MD, de Courten B, et al. Metformin use associated with reduced risk of dementia in patients with diabetes: a systematic review and meta-analysis. *J Alzheimers Dis* 2018;65:1225-36.
- Ping F, Jiang N, Li Y. Association between metformin and neurodegenerative diseases of observational studies: systematic review and meta-analysis. *BMJ Open Diabetes Res Care* 2020;8:e001370.
- Kuan Y-C, Huang K-W, Lin C-L, et al. Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus. *Prog Neuropsychopharmacol Biol Psychiatry* 2017;79:77-83.
- Sluggert JK, Koponen M, Bell JS, et al. Metformin and Risk of Alzheimer's Disease Among Community-Dwelling People With Diabetes: A National Case-Control Study. *J Clin Endocrinol Metab* 2020;105:e963-72.
- Shi Q, Liu S, Fonseca VA, et al. Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus. *BMJ Open* 2019;9:e024954.
- Qin X, Zhang X, Li P, et al. Association Between Diabetes Medications and the Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis. *Front Neurol* 2021;12:1155.
- Wallace PJ, Shah ND, Dennen T, et al. Optum Labs: building a novel node in the learning health care system. *Health Aff* 2014;33:1187-94.
- Overhage JM, Ryan PB, Reich CG, et al. Validation of a common data model for active safety surveillance research. *J Am Med Inform Assoc* 2012;19:54-60.
- Newby D, Prieto-Alhambra D, Duarte-Salles T, et al. Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study. *Alzheimers Res Ther* 2020;12:38.
- European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. *The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCEPP) Guide on Methodological Standards in Pharmacoepidemiology (Revision 8)*. EMA/95098/2010 Rev.8. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance, 2010. http://www.encepp.eu/standards_and_guidances/documents/GuideMethodRev8.pdf
- Curtis LH, Hammill BG, Eisenstein EL, et al. Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. *Med Care* 2007;45:S103-7.
- Groenwold RHH, White IR, Donders ART, et al. Missing covariate data in clinical research: when and when not to use the missing-indicator method for analysis. *CMAJ* 2012;184:1265-9.
- Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. *Stat Med* 2009;28:3083-107.
- Arnold BF, Ercumen A, Benjamin-Chung J, et al. Brief report: negative controls to detect selection bias and measurement bias in epidemiologic studies. *Epidemiology* 2016;27:637-41.

- 31 Scherrer JF, Salas J, Floyd JS, *et al.* Metformin and sulfonylurea use and risk of incident dementia. *Mayo Clin Proc* 2019;94:1444–56.
- 32 Davis KAS, Mueller C, Ashworth M, *et al.* What gets recorded, counts: dementia recording in primary care compared with a specialist database. *Age Ageing* 2021;50:2206–13.
- 33 McKhann GM, Knopman DS, Chertkow H, *et al.* The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging–Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 2011;7:263–9.
- 34 Charpignon M-L, Vakulenko-Lagun B, Zheng B. Drug repurposing of metformin for Alzheimer's disease: Combining causal inference in medical records data and systems pharmacology for biomarker identification. *medRxiv* 2021:2021.08.10.21261747.
- 35 Weinstein G, Davis-Plourde KL, Conner S, *et al.* Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer's disease: pooled analysis from 5 cohorts. *PLoS One* 2019;14:e0212293.
- 36 Ha J, Choi DW, Kim KJ. Association of metformin use with Alzheimer's disease in patients with newly diagnosed type 2 diabetes: a population-based nested case–control study. *Scientific Reports* 2021;11:1:1–9.
- 37 Zheng J, Xu M, Walker V. Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer's disease risk in the general population: a Mendelian randomisation study. *Diabetologia* 2022;2022:1–12.
- 38 Luchsinger JA, Perez T, Chang H, *et al.* Metformin in amnesic mild cognitive impairment: results of a pilot randomized placebo controlled clinical trial. *J Alzheimers Dis* 2016;51:501–14.
- 39 Sportelli C, Urso D, Jenner P, *et al.* Metformin as a potential neuroprotective agent in prodromal Parkinson's Disease-Viewpoint. *Front Neurol* 2020;11:556.
- 40 Mor DE, Sohrabi S, Kaletsky R, *et al.* Metformin rescues Parkinson's disease phenotypes caused by hyperactive mitochondria. *Proc Natl Acad Sci U S A* 2020;117:26438–47.
- 41 Lee ATC, Richards M, Chan WC, *et al.* Higher dementia incidence in older adults with type 2 diabetes and large reduction in HbA1c. *Age Ageing* 2019;48:838–44.
- 42 Haw JS, Shah M, Turbow S. Diabetes complications in racial and ethnic minority populations in the USA. *Curr Diab Rep* 2021;21:1–8.
- 43 Lourida I, Soni M, Thompson-Coon J, *et al.* Mediterranean diet, cognitive function, and dementia: a systematic review. *Epidemiology* 2013;24:479–89.
- 44 Okunoye O, Marston L, Walters K, *et al.* Change in the incidence of Parkinson's disease in a large UK primary care database. *NPJ Parkinsons Dis* 2022;8:23.
- 45 Zdanys K, Tampi RR. A systematic review of off-label uses of memantine for psychiatric disorders. *Prog Neuropsychopharmacol Biol Psychiatry* 2008;32:1362–74.
- 46 Schwartz TL, Siddiqui UA, Raza S. Memantine as an augmentation therapy for anxiety disorders. *Case Rep Psychiatry* 2012;2012:1–3.
- 47 Fereshtehnejad S-M, Yao C, Pelletier A, *et al.* Evolution of prodromal Parkinson's disease and dementia with Lewy bodies: a prospective study. *Brain* 2019;142:2051–67.
- 48 Vermunt L, Sikkes SAM, van den Hout A, *et al.* Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. *Alzheimers Dement* 2019;15:888–98.
- 49 Maruthur NM, Tseng E, Hutfless S, *et al.* Diabetes medications as monotherapy or Metformin-Based combination therapy for type 2 diabetes: a systematic review and meta-analysis. *Ann Intern Med* 2016;164:740–51.
- 50 Metformin in Alzheimer's Dementia Prevention - Full Text View - ClinicalTrials.gov. Available: <https://clinicaltrials.gov/ct2/show/NCT04098666> [Accessed 9 May 2022].